Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
With the need for non-destructive analytical procedures, NIR and Raman spectroscopy are expanding. Rising demand for these technologies. Spectroscopic technologies enable sample examination without altering integrity, making them valuable in agriculture, food and beverage processing, and pharmaceuticals.
For quality control, content uniformity, and raw material analysis, pharmaceutical businesses use NIR and Raman spectroscopy. The pharmaceutical industry uses both spectroscopies. The firm needs this spectroscopy. These technologies enable accurate, quick measurements for pharmaceutical manufacturing.
Market growth is driven by NIR and Raman spectroscopy equipment technology. As instrument sensitivity, data processing software, and portable devices increase, these spectroscopic approaches are becoming more accessible and user-friendly across industries. Common.
Industrial Process Analytical Technology (PAT) efforts have raised Raman and near-infrared spectroscopy demand. With these analytical methods, PAT monitors and controls production in real time to ensure quality and efficiency. It fits these analytical approaches.
Raman and near-infrared (NIR) spectroscopy are increasingly employed in food and beverage quality control, compositional analysis, and shelf-life prediction. Each application is gaining prominence. These methods help companies maintain product quality and comply with laws with rapid, non-destructive insights. They help companies comply with regulations.
Agriculture and environmental monitoring are key applications of near-infrared and Raman spectroscopy. These approaches make soil composition, nutrient levels, and environmental contaminants easier to analyze. Thus, environmental scientists and farmers have the information they need to choose ecologically friendly farming practices.
To meet tight regulatory criteria, such as those for food and pharmaceutical companies, strong analytical methods must be used. NIR and Raman spectroscopy are increasingly used to satisfy regulatory criteria and ensure product quality. This is because these spectroscopies provide precise, repeatable findings.
Globalization in the pharmaceutical and chemical industries has made product quality standardization and uniformity increasingly crucial. This is because these sectors are increasingly intertwined. Near-infrared and Raman spectroscopy are being used more to meet international quality standards. Due to their adaptability, these spectroscopies may be employed in many locations.
NIR and Raman spectroscopy have many benefits, but their application is difficult. Users may struggle with device calibration, sample variability, and numerical data interpretation. To solve these issues, software advances and standardization are being sought.
The rise of medicines, agriculture, and chemicals in developing nations is driving the non-infrared and Raman spectroscopy industry. Due to increased understanding of the advantages of these spectroscopic procedures, economic growth zones are implementing them.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Growth Rate | Â Â 7.60% |
Glioblastoma Market Highlights:
Global Glioblastoma Market Overview
The Glioblastoma Market Size was valued at USD 2.98 Billion in 2023. The Global Glioblastoma industry is projected to grow from USD 3.21 Billion in 2024 to USD 5.97 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.05% during the forecast period (2024 - 2032). Glioblastoma is a type of brain tumor.The increasing occurrences of glioblastoma, a type of brain tumor, coupled with extensive research in glioblastoma treatment, and the rising adoption of chemotherapy are expected to fuel the growth of the glioblastoma market. However, the high cost of drugs and the failure of drug candidates in clinical trial phases are anticipated to hamper the market growth.
Glioblastoma Market Trends
The increasing incidence rate of glioblastoma is expected to fuel the growth of the glioblastoma market. According to the statistics published in 2017 by the National Centre for Biotechnology Information (NCBI), glioblastoma has an incidence rate of 3.19 per 100,000 persons in the US. The growing prevalence indirectly increases the healthcare expenditure of the people as well as the government. This motivates the players operating in the market to come up with alternatives for the treatment of glioblastoma. Thus, this is likely to fuel the growth of the global glioblastoma market during the forecast period.
Glioblastoma Market Segment Insights
The global glioblastoma market has been segmented by type, treatment, and end user. The market, based on type, has been bifurcated into primary glioblastoma and secondary glioblastoma. Based on treatment, the glioblastoma market has been segregated into surgical procedure, radiation therapy, chemotherapy, and others. The global glioblastoma market, based on end user, has been divided into hospitals, specialty clinics and centers, and others. The specialty clinics and centers held a share of 36.8% in 2018.
Glioblastoma Regional Insights
The glioblastoma global market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to dominate the global glioblastoma industry. The growth in this region can be attributed to the increased cases of glioblastoma and brain tumors. Moreover, the approval of drugs helps in maximizing the growth of the market in this region.
Europe held a substantial share in the global glioblastoma market. This can be attributed to a large number of clinical trials in the region. For instance, Merck KGaA along with Vaximm GmbH is involved in Phase I and II trials to evaluate the efficacy and safety of VXM01 in combination with Avelumab in patients with resectable and non-resectable progressive glioblastoma following tumor resection and radio-chemotherapy containing temozolomide.
Asia-Pacific is estimated to be the fastest-growing region in the global market. The rise in the improved healthcare infrastructure promises a high level of research on the treatment of glioblastoma in the region.
The glioblastoma market in the Middle East & Africa is expected to witness a modest market growth rate from 2019 to 2025. The Middle East would lead the market growth in this region. Rising awareness regarding health and availability of new treatment methods are expected to drive the market growth during the assessment period.
Key Players
The prominent players in the global glioblastoma market are
- F. Hoffmann-La Roche Ltd (Switzerland)
- Arbor Pharmaceuticals, LLC (US)
- Merck & Co., Inc. (US)
- Sun Pharmaceutical Industries Ltd (India)
- Amgen Inc. (US)
- Teva Pharmaceutical Industries Ltd (Israel).
Some of the key strategies followed by players operating in the global glioblastoma market were innovation, product development, and acquisition & mergers.
- In May 2019 Merck entered into a definitive agreement to acquire Peloton Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company, focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases.
- In January 2018 Amgen and Allergan PLC received the approval by the European Commission (EC) for the marketing authorization of MVASI for the treatment of glioblastoma as well as certain types of cancers.
- In November 2016 Sun Pharma acquired Biosintez, a Russian pharmaceutical company engaged in the manufacturing and marketing of pharmaceutical products.
Glioblastoma Market Segmentation
Glioblastoma Type Outlook
- Primary Glioblastoma
- Secondary Glioblastoma
Glioblastoma Treatment Outlook
- Surgical Procedure
- Radiation Therapy
- Chemotherapy
- Others
Glioblastoma End User Outlook
- Hospitals
- Specialty Clinics and Centers
- Others
Glioblastoma Region Outlook
- Americas
- North America
- US
- Canada
- Latin America
- North America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Available Additional Customizations
- Mega Trends in the Market
- Glioblastoma Market: Challenges
Intended Audience
- Pharmaceutical companies
- Contract research manufacturing organizations
- Research & development organizations
- Academic institutes
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
